Serum iron concentration and plasma oxidant-antioxidant balance in patients with chronic venous insufficiency

Magdalena Budzyń1ACDEFG, Maria Iskra1ACDEFG, Zbigniew Krasiński2ACDEFG, Łukasz Dzieciuchowicz2ACDEFG, Magdalena Kasprzak1CD, Bogna Grzyczyńska1CD

1 Department of General Chemistry, Chair of Chemistry and Clinical Biochemistry, Poznan University of Medical Sciences, Poznan, Poland
2 Department of General and Vascular Surgery, Poznan University of Medical Sciences, Poznan, Poland

Source of support: The study was supported by the University of Medical Science in Poznan (Grant no. 501-01-0228370-03102-50564)

Summary

Background: The aim of this study was to evaluate serum iron concentration and influence of this element on biomarkers of oxidative stress in patients affected by chronic venous insufficiency (CVI).

Material/Methods: Serum iron (SI) concentration and plasma parameters of oxidant-antioxidant balance (i.e., malonyldialdehyde [MDA], uric acid [UA] concentration, and total antioxidant capacity [TAC]) were compared between 35 patients divided into appropriate groups and 23 healthy individuals.

Results: The subgroups analysis showed that SI concentration was significantly higher only in patients with shorter duration of CVI in comparison with the control group (P=0.013). Significant, negative correlation was found between SI concentration and duration of the disease (r=–0.422, P=0.014), age of the patients (r=–0.542, P=0.001) and BMI (r=–0.408, P=0.018). Mean value of MDA concentration and TAC capacity were higher in patients with CVI in comparison with healthy individuals (P<0.05). UA concentration was decreased, especially in CVI patients with mild clinical stage of disease and shorter CVI duration (P=0.047; P=0.034). There was no significant correlation found between SI concentration and the parameters of oxidant-antioxidant balance.

Conclusions: High concentration of MDA and low UA level in blood of CVI patients suggests that oxidative stress plays an important role in the pathogenesis of the disease. The increase in SI concentration observed in the early stage of CVI can enhance free radicals formation; however, direct evidence has not been provided by the present study.

key words: chronic venous insufficiency • serum iron concentration • malonyldialdehyde • total antioxidant capacity • reactive oxygen species

Full-text PDF: http://www.medscimonit.com/fulltxt.php?ICID=882132

Word count: 4523
Tables: 4
Figures: 5
References: 56

Author’s address: Magdalena Budzyń, Department of General Chemistry, Chair of Chemistry and Clinical Biochemistry, Poznan University of Medical Sciences, 6 Grunwaldzka Str., 60-780 Poznan, Poland, e-mail: magdalena.budzyn@wp.pl
**BACKGROUND**

Histological examination of specimens taken from patients with CVI demonstrates many pathological changes in the structure of the vein wall. The main alterations are observed within the intima, which increases in thickness and crumples, forming an irregular surface. In some parts of the intima, endothelial cells are fragmented into pieces, with destruction of subendothelial tissue and desquamation of some cellular fragments into the lumen [1]. Histological observations are supported by biochemical studies indicating high level of endothelial damage markers, such as endotheli-um-derived adhesion molecules and circulating endothelium cells, in blood of patients with CVI [2,3]. It is highly probable that the increase in endothelial permeability may be the first step in the pathological remodeling of the vein wall observed in patients with CVI. However, the mechanisms and factors involved in this process are still unknown.

In some cardiovascular disorders, such as coronary artery disease, hypertension, and diabetes, reactive oxygen species (ROS) are found to be one of the factors promoting vascular injury [4–6]. Some experiments with monolayers of cultured endothelium demonstrated that ROS induce cytolys-is of endothelial cells and disruptions in endothelial cell adhesion [7,8]. The mechanism of these destructive effects on vascular endothelium is not fully understood, but it may result from the ability of ROS to promote oxidative modifi-cation of biomolecules, from the degradation of extracel-lular components, or it may be related to their capacity to induce receptor-mediated cell apoptosis [9,10].

It is postulated that activated neutrophils are mainly involved in ROS generation in the pathogenesis of CVI [11,12]. However, high level of body iron observed in patients with CVI suggests that these metal ions may be another independent-source of ROS production. It is well known that iron ions in high concentration can participate in Fenton reaction and generate hydroxyl radical. Deposits of iron have been detected in the skin of lower limbs, and in the urine and inguinal lymph nodes of patients with CVI [13,15]. Moreover, in tissue and serum samples collected from patients’ legs, high values of total iron concentration and iron-laden macrophages were observed [16]. Although these studies suggest that iron overload may be involved in the pathogenesis of CVI, there is still no evidence proving iron ions contribution to ROS production as a probable mecha-nism of their influence on the development of CVI. For this reason, the aim of our study was to evaluate SI concentra-tion along with the parameters of oxidant-antioxidant bal-ance – malonyldialdehyde (MDA), uric acid (UA) concentra-tion and total antioxidant capacity (TAC) – in peripheral blood of patients affected by CVI.

**MATERIAL AND METHODS**

**Patients**

The group of patients consisted of 35 subjects (24 women and 11 men) with CVI, aged 27–68 years. After a medical interview, physical examination and duplex ultrasonogra-phy, the patients were considered for varicose vein opera-tion. The CVI patients demonstrated venous reflux in the greater saphenous vein; 80% of them with III/IV degree and 20% with II degree. In the study, patients were divid-ed into 2 subgroups according to the clinical severity of the disease. **Group M** consisted of 12 patients with mild clinical symptoms of CVI, each of whom fell into 1 of the 2 clinical classes – C2 or C3 – in the CEAP classification, with varicose veins (C2) and associated ankle edema (C3). **Group S** consisted of 23 patients with severe clinical symptoms of CVI, each of whom fell into 1 of the 3 classes – C4, C5, C6 – in the CEAP classification, with some changes in the skin ascribed to venous disease: pigmentation, lipodermatosclero-sis (C4), healed ulceration (C5), and active ulceration (C6) (Figure 1). The patients were also divided according to the duration of the disease. **Group I** consisted of 15 patients with disease duration up to 10 years and **Group II** consisted of 20 patients with disease duration of more than 10 years. Other factors such as sex, age, and BMI value were also taken into consideration. All parameters were analyzed in the group of males and females separately. Patients were divid-ed into 2 age groups: up to 50 years old (n=14) and over 50 years old (n=21). The influence of BMI on the analyzed parameters was also investigated. Patients were divided into those with the normal BMI value (<25) (n=18) and those who were overweight (BMI value greater than 25) (n=17).

The control group consisted of 23 individuals (16 women and 7 men), aged 27–61, all of whom were members of the medical staff, without any signs of CVI. Subjects with dia-betes, hypertension, coronary artery disease, and tumors were excluded from both the study and the control groups.

Blood samples were taken from the arm and added to the tubes with and without K<sub>E</sub>EDTA. After 30 minutes, the tubes were centrifuged at 3000 rpm for 15 minutes to obtain plasma and serum. Serum and plasma samples were stored at a temperature of −80°C until all of assays were performed. The study procedure was approved by the Bioethical Committee of the University of Medical Sciences in Poznan, and informed consent was obtained from all the participants.

**Experimental**

**Reagents and apparatus**

All the reagents used in the study (thioarbituric acid [TBA], butylated hydroxytoluen [BHT], 1,1,3,3-tetramethoxypropan [TMP], n-butanol, 2,2'-azobis(2-amidopropane) hydrochloride [AAPH], 2'-azinobis(3-ethylbenzothiazoline-6-sulfonic acid) [ABTS], and sodium dodecyl sulfate [SDS]) were of analytical grade and purchased from the Sigma Chemical Company. The spectrophotometric measurements were carried out on a Hitachi UV/VIS U-2900 Spectrophotometer.

**Serum iron concentration assay**

Serum iron (SI) concentration was measured using the commercially available Biomaxima kit (Biomaxima, Poland). According to the procedure, serum iron ions bound to transferrin are released by guanidine hydrochloride, reduced to ferrous ions and subsequently complexed by Ferrosyn to form a coloured product with an absorbance maximum at 560 nm.

Lowest level of detection was 0.90 μmol/L iron. Linearity limit was 179 μmol/L iron. Within-run precision of duplicates
within-run precision of duplicates varied between 2.5% and 5.5%. The reproducibility of the method was from 3.5% to 5.5%.

**MDA assay**

Plasma MDA concentration, one of the final products of lipid peroxidation, was measured as a thiobarbituric acid reactive substance/s (TBARS) by the method of Buege and Aust [17] modified by Jentzsch [18]. This procedure is based on the formation of a pink colored complex between MDA and thiobarbituric acid (TBA), with an absorbance maximum at 532 nm. 0.5 mL of plasma was added to the reaction mixture formed by equal parts of 15% trichloroacetic acid, 0.25 mol/L HCl, and 0.375% TBA with the addition of 0.1 mL of 2,5 mmol/L butylated hydroxytoluene (BHT) and 8.1% sodium dodecyl sulfate (SDS). The mixture was heated for 30 minutes at a temperature of 95°C; after cooling, the chromogen was extracted with n-butanol and centrifuged. The absorbance of the organic layer was measured at 532 nm. To correct for background absorption, absorbance values at 572 nm were subtracted from those at 532 nm, the latter representing the absorption maximum of 2:1 TBA:MDA adducts. The results were read from the calibration curve prepared by serial dilutions of a tetramethoxypropan (TMP) stock solution (0–50 nmol/mL) using ethanol as a diluent. The reproducibility of the method varied between 5.5% and 7.6%. The reproducibility of the method was from 5.1% to 5.9%.

**Total antioxidant capacity assay (TAC)**

To evaluate plasma total antioxidant capacity, a simple spectrophotometric method, based on the determination of peroxyl radical trapping capacity was used [19]. In this method, the decomposition reaction of 2,2’-azobis(2-aminopropane) hydrochloride (AAPH) at 37°C is the source of peroxyl and alkoxyl radicals which oxidize 2,2’-azinobis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) to a green cation radical. Antioxidants present in plasma inhibit the reaction, and the induction time of the reaction acts as a parameter enabling the determination of antioxidant capacity. In this assay, 890 µL of phosphate buffer (100 mmol/L, pH 7.0) previously warmed to 37°C, 30 µL of 5 mmol/L ABTS, and 10 µL of plasma were added to the cuvette. In the next step, 100 µL of 200 mmol/L AAPH was added to the reaction mixture and all the reagents were thoroughly mixed. The cuvette was placed in a spectrophotometer with the temperature adjusted to 37°C, and absorbance value at 414 nm was monitored for about 15 minutes with automatic measurement every 15 seconds. The inhibition time of the starting reaction was directly proportional to the activity of antioxidants in each sample. The results were calculated from the calibration curve prepared by serial dilutions of Trolox stock solution (0–7 µmol/L) using ethanol as a diluent. The repeatability of the method varied between 5.5–6.5%. The reproducibility of the assay was from 5.7% to 7.3%.

**Uric acid concentration (UA)**

Serum uric acid was assessed by uricase enzymatic method, using the commercially available Biomaxima kit (Biomaxima, Poland). According to the procedure, uricase transforms uric acid into allantoin and hydrogen peroxide in the sample. By the action of peroxidase and in the presence phenol-derivatives, 2,3-Dihydroxybenzoyslerine (DHBS) and 4-aminantypyrine, hydrogen peroxide gives a coloured product which can be measured at 520 nm. Lowest level of detection was 8.33 µmol/L uric acid. Linearity limit was 1190 µmol/L uric acid. Within-run precision of duplicates varied between 1.0% and 2.0%. The reproducibility of the method varied between 2.6% and 3.0%.

**Statistical analysis**

Data are expressed as mean ± standard deviation. The distribution of variables was assessed using the Kolmogorov-Smirnov test. Comparisons between CVI patients and the control group were evaluated with Student’s unpaired T test and the Mann-Whitney U test according to the distribution of variables. The Pearson or the Spearman correlation coefficient was used to test the strength of any associations between different variables. In all cases, P value ≤0.05 was considered significant.

**Results**

**Iron concentration**

In patients with CVI, the mean value of SI concentration was elevated when compared with the control group, but did not reach statistical significance (Table 1). After classifying...
patients into appropriate subgroups according to the clinical severity of the disease, similar observation was made. In both the M and S groups (patients with mild and severe stage of CVI) SI concentration was not significantly different in comparison with healthy subjects (group M: 23.20±7.79 vs. control: 18.75±4.39, P=0.104; group S: 20.91±4.20 vs. control: 18.75±4.39, P=0.111) (Figure 2). However, the group of patients with disease duration up to 10 years (group I) showed significantly elevated concentration of iron compared with the control group and compared with the group of patients with a longer disease duration (group I: 24.30±6.65 vs. control: 18.75±4.39, P=0.013; group I: 24.30±6.65 vs. group II: 19.73±3.90, P=0.033) (Figure 2). Any significant difference in SI concentration between patients with more than 10 years disease duration and healthy subjects was not found (19.73±3.90 vs. 18.75±4.39, P=0.466) (Figure 2). In both CVI male and CVI female groups SI concentration was similar and did not differ significantly (Table 2). In patients aged 50 or less SI concentration was significantly higher than in those over 50 years old; *** P≤0.05; the patients with proper BMI vs. patients with BMI >25.

Table 1. Serum iron concentration and biochemical parameters of plasma oxidant – antioxidant balance in the CVI patients and the control group.

| Parameter                        | Control group | Patients with CVI | P value |
|----------------------------------|---------------|-------------------|---------|
| Serum iron concentration (SI) µmol/L | 18.75±4.39    | 21.67±5.64        | >0.05   |
| Malonyldialdehyde (MDA) nmol/mL  | 3.43±1.55     | 5.17±1.73*        | <0.001  |
| Total antioxidant capacity (TAC) µmol of Trolox equiv./L | 714±131       | 805±165*          | <0.05   |
| Uric acid concentration (UA) µmol/L | 305±50        | 271±78            | >0.05   |

All data are presented as the mean ± standard deviation; * statistically significant.

Table 2. The influence of some factors, such as: gender, age and BMI on the serum iron concentration and biochemical parameters of oxidant – antioxidant balance in CVI patients.

| Factor   | SI (µmol/L) | MDA (nmol/mL) | TAC (µmol Trolox equiv./L) | UA (µmol/L) |
|----------|-------------|---------------|---------------------------|-------------|
| Gender   | Female (n=23) | 22±6.11      | 5.70±1.61*                | 760±152     | 246±62      |
|          | Male (n=12)  | 20.41±4.66   | 4.07±1.49                 | 889±155*    | 329±82*     |
| Age      | ≤50 years (n=14) | 25.68±6.53** | 5.23±1.88                 | 813±165     | 265±90      |
|          | >50 years (n=21) | 19.07±2.91   | 5.13±1.68                 | 800±169     | 266±60      |
| BMI      | ≤25 (n=18)   | 22.40±6.08   | 5.15±1.76                 | 745±141     | 241±64      |
|          | >25 (n=17)   | 20.27±4.72   | 5.13±1.80                 | 885±152***  | 306±82***   |

All data are presented as the mean ± standard deviation. * P≤0.05; the female CVI group vs. the male CVI group; ** P≤0.05; the patients aged 50 or less vs. patients over 50 years old; *** P≤0.05; the patients with proper BMI vs. patients with BMI >25.

Figure 2. The SI concentration in the control group and in CVI patients classified into appropriate groups according to severity and duration of disease (Group M – patients with mild clinical stage of CVI, Group S – patients with severe clinical stage of CVI, Group I – patients with CVI duration up to 10 years, Group II – patients with CVI duration more than 10 years). * P≤0.05, Group I vs. Control; ** P≤0.05, Group I vs. Group II.

MDA concentration

The mean concentration of MDA in plasma of patients with CVI was significantly higher than in the control group (Table 1). There was a raised concentration of MDA observed in both M and S groups, as well as in groups I and
The correlation coefficients for serum iron concentration and parameters of plasma oxidant—antioxidant balance, age, BMI and duration of disease.

| Serum iron concentration (SI) (µmol/L) |  |  |
|--------------------------------------|---|---|
|                                     | r | P  |
| Malondialdehyde (MDA) (nmol/mL)     | 0.102 | 0.572 |
| Total antioxidant capacity (TAC) (µmol Trolox equiv./L) | -0.152 | 0.397 |
| Uric acid concentration (UA) (µmol/L) | -0.318 | 0.071 |
| Age (years)                          | -0.542 | 0.001* |
| BMI (kg/m²)                          | -0.408 | 0.018* |
| Duration of disease (years)          | -0.422 | 0.014* |

* Statistically significant.

The TAC of plasma in the control group and in CVI patients classified into appropriate groups according to severity and duration of disease (Group M – patients with mild clinical stage of CVI, Group S – patients with severe clinical stage of CVI, Group I – patients with CVI duration up to 10 years, Group II – patients with CVI duration more than 10 years). * P≤0.05, appropriate group vs. Control.

The mean value of plasma TAC of patients affected by CVI was significantly higher compared with healthy subjects (Table 1). A significant difference in TAC value was found mainly in the patients with a severe clinical stage of CVI (group S) or with more than 10 years duration of the disease (group II) (group S: 825±164 vs. control: 714±131, P=0.016; group II: 896±175 vs. control: 714±131, P=0.013) (Figure 4).

It was demonstrated that the sex of patients affects plasma TAC. The value of this parameter was significantly lower in the group of women with CVI than in the group of men with the same disease (Table 2). However, TAC plasma was still significantly higher in CVI women compared with the female control group (760±152 vs. 661±90, P=0.040). The age of patients did not influence plasma TAC, because in patients aged 50 or less its value was similar to the one observed in patients who were over 50 years old (Table 2).

Surprisingly, patients with BMI value over 25 show a higher plasma TAC than patients with BMI value lower than 25 (Table 2). Moreover, BMI of CVI patients correlated positively with plasma TAC (r=0.383, P=0.025). No relationship was found between plasma TAC and SI concentration in patients with CVI (Table 3).

**Figure 3.** The MDA concentration in the plasma of control group and CVI patients classified into appropriate groups according to severity and duration of disease (Group M – patients with mild clinical stage of CVI, Group S – patients with severe clinical stage of CVI, Group I – patients with CVI duration up to 10 years, Group II – patients with CVI duration more than 10 years). * P≤0.05, appropriate group vs. Control.

**Figure 4.** The TAC of plasma in the control group and in CVI patients classified into appropriate groups according to severity and duration of disease (Group M – patients with mild clinical stage of CVI, Group S – patients with severe clinical stage of CVI, Group I – patients with CVI duration up to 10 years, Group II – patients with CVI duration more than 10 years). * P≤0.05, Group S, Group II vs. Control.
the difference was not significant (Table 1). The statistically significant decrease in UA was observed only in the patients with a mild clinical stage of the disease (Group M) or up to 10 years CVI duration (Group I) (group M: 260±75 vs. control: 305±50, *P* ≤0.047; group I: 259±90 vs. control: 305±50, *P* ≤0.034) (Figure 5). The UA concentration was significantly lower in CVI women compared with CVI men (Table 2). Moreover, UA concentration remained significantly lower in CVI women in comparison with the female control group (246±62 vs. 292±43, *P* ≤0.014). This last finding was not noticed in the case of CVI men, whose UA concentration was also lower compared with the male control group, but did not reach statistical significance (329±82 vs. 341±51, *P* ≤0.752).

As shown in Table 2, some decrease in UA concentration was found in patients with normal BMI compared to those who were overweight. The age of patients did not influence UA, because in patients aged 50 or less its value was similar to the one observed in patients who were over 50 years old (Table 2). In univariate analysis a significant negative correlation was found between UA and MDA concentration in CVI patients (r=−0.414, *P* ≤0.017). Moreover, UA concentration correlated positively with TAC value of CVI patients (r=0.496, *P* ≤0.005). No association was found between UA and SI concentration in CVI patients (Table 3).

### DISCUSSION

In the pathogenesis of diseases associated with vascular injury, ROS are thought to be one of the most important factors promoting damage to the endothelium, resulting in the loss of its integrity [20–22]. It is highly probable that the pathological changes in the structure of the vein wall observed in CVI are caused by ROS overproduction. ROS promote the oxidation of important biomolecules such as proteins, lipids, and DNA, assessed in the biological samples as the markers of oxidative stress [23]. In our study, we demonstrated an increased concentration of MDA, a marker of lipid peroxidation, in the plasma of patients with CVI. However, no statistically significant association between MDA concentration and the duration and severity of CVI was found. Our data are in agreement with previously published studies in which high MDA concentration was detected in blood and tissue homogenates of patients with CVI. Kozka et al showed a significantly higher concentration of MDA in plasma of 31 patients with varicose veins of the second and third degree, according to CEAP classification, compared with 31 healthy volunteers [24]. However, the same authors reported a significantly positive correlation between BMI and an increased MDA concentration, which was not confirmed by our study. High concentration of MDA was also reported in homogenates prepared from segments of the greater saphenous vein of patients with varicose vein and with healed venous ulcers [25,26]. These findings indicate that oxidative stress can play an important role in the pathogenesis of CVI and occur in the early stage of the disease development.

In our study, we demonstrated that CVI women can be more susceptible to negative effects of oxidative stress than can CVI men, which was manifested by a higher concentration of MDA in the plasma of the female group. Similar results were obtained by Krzyściak et al, who detected locally increased concentration of MDA in blood samples taken from the lower limbs compared with the samples of peripheral blood of the same subjects, especially among women [27].

Oxidative stress, which is a consequence of ROS overproduction, can influence the antioxidant status of patients with CVI. Our study demonstrated an increased TAC of plasma, especially in the group of patients with the severe clinical stages of CVI and more than 10 years of disease duration. In our opinion, high value of plasma TAC suggests an up-regulation of antioxidant activity to counterbalance an increasing oxidative activity. The same explanation was used by Yeoh-Ellerton et al., who observed higher TAC status of chronic ulcer wound fluids collected from patients with symptoms of venous disease compared to acute wound fluids [28]. It is well known that in conditions related to an elevated ROS generation, such as sepsis, atherosclerosis, and diabetes, the increase in plasma total antioxidant capacity is very often detected. It may represent the antioxidant adaptation for avoiding oxidative damage [29–31]. This adaptive mechanism can prevent further oxidation of biomolecules, being reflected as the lack of any significant difference in MDA concentration between patients with the mild and severe clinical stages of CVI, as well as between patients with a shorter or longer duration of the disease. However, in patients with CVI, prolonged blood stasis causes hypoxia of tissues, which can activate xanthine oxidase and lead to the overproduction of uric acid, a major component responsible for plasma antioxidant capacity. In our study we found that the uric acid concentration in serum of CVI patients has a tendency to decrease rather than to increase. Moreover, low concentration of uric acid was associated with low TAC value and high MDA concentration. This suggests that in the pathogenesis of CVI, uric acid is oxidized, losing its biological activity as an antioxidant, and negatively influencing plasma TAC. Our findings confirm previous research indicating significant elevation of allantoin: uric acid percentage ratio in wound fluids collected from patients with CVI [32]. In our study, a greater decrease in uric acid concentration was demonstrated in CVI women, implying that CVI women are less protected against the oxidative stress, which explains the higher MDA concentration and lower TAC value associated with the female CVI group. Although the concentration of uric acid decreases, the TAC value of CVI patients remains elevated compared with healthy subjects. It is highly probable that insufficient activity of one
antioxidant increases concentration of others to maintain the oxidative-antioxidant balance. For this reason, the concentration of some other endogenous antioxidants in CVI patients should be evaluated in further studies.

Many studies have shown that ROS can play a critical role in CVI development; therefore, the mechanisms which lead to the overproduction of free radicals in the pathogenesis of venous disease need to be investigated. It is well known that activated neutrophils, detected in blood of patients with CVI, can produce and liberate a great amount of ROS to body fluids. However, since 1988, when Ackerman et al reported an increased concentration of iron level in the skin of patients with venous ulcerations, the role of this element as an alternative source of ROS has been considered [13]. Iron, as an indispensable element involved in many processes vital for life, can promote the production of an extremely reactive hydroxyl radical (OH•) via the Fenton reaction, in conditions related to high iron storage. There is growing epidemiologic evidence of a relationship between the level of iron and cardiovascular diseases [33–35]. It is suggested that the catalytic role of iron in lipid peroxidation may be an important factor in developing atherosclerotic lesions [36–39]. An increasing number of studies have demonstrated high iron concentration in serum, wound fluids and tissue biopsies taken from patients with CVI [13–16]. Strong evidence of the relationship between iron and venous diseases was provided by the Zamboni study, which showed that a mutation of the HFE gene encoding the iron regulatory protein, found in people with hereditary hemochromatosis, a disease associated with an abnormal iron accumulation, increases the risk of ulcers in primary chronic venous insufficiency [40]. The same author demonstrated an elevated iron concentration in serum obtained from the lower limbs of patients with CVI compared with the samples from the arm of the same subjects [16]. Wenk et al observed a higher level of iron in the chronic exudates of patients suffering from venous ulcers compared with acute wound fluids from patients who had undergone a mastectomy [41]. Moreover, the high level of iron storage shown as an elevated concentration of ferritin, an iron binding protein, was detected in serum, wound fluids and tissue biopsies taken from the lower limbs of patients with CVI [16,28].

In the present study determination of SI concentration was chosen as a routine and fast method for screening for iron level in blood of CVI patients. We demonstrated a non-significant trend towards an increased SI concentration in patients with CVI. Interestingly, the significantly higher value of SI was found in serum of those patients with a shorter duration of disease (ie, up to 10 years). We reported that SI concentration decreases as the duration of disease increases. This process can be explained by the iron escaping from systemic circulation to different tissues because of an increase in endothelium permeability. For this reason, in patients suffering from CVI for a longer period of time, some deposits of iron, especially in the skin of lower limbs, are very often detected. Moreover, we reported that younger CVI patients are exceptionally predisposed to a high SI concentration, as confirmed by an increased SI concentration in the group of patients aged 50 or less compared to those over 50 years and by a statistically significant negative correlation found between SI concentration and age. It cannot be stated confidently whether this effect is connected with some pathological processes accompanying CVI or whether it is caused by physiological mechanism that leads to the decrease in SI concentration in the elderly people, probably associated with defective intestinal iron absorption [42]. However, in the control group no inverse relationship between age and SI concentration was found. Moreover, multiple linear regression revealed that age is an independent and negative parameter influencing SI concentration in the group of woman with CVI. In the present work we observed that BMI of patients also affected SI concentration. The significantly lower concentration of iron was demonstrated in overweight patients compared to those with a normal BMI value. This observation correlates with previous published data indicating an inverse relationship between iron status and obesity [43–45]. The etiology of the iron deficiency is uncertain but it is postulated that it may be caused by an iron-poor diet, a greater iron requirement because of the larger blood volume of obese adults, or improper inflammatory-mediated sequestration of iron ions in the reticuloendothelial system.

In this study the hypothesis that iron contributes to ROS production was tested; therefore the relationship between SI concentration in patients with CVI and the biomarkers of the oxidative stress was analyzed. The effect of iron on ROS production seems to be indirect because its level did not correlate with studied markers of oxidant-antioxidant balance.

However, lack of this relationship does not exclude the ability of iron to ROS generation. In our study we used rather non-specific parameter of iron status, which may be affected by factors other than amount of body iron. Inflammation accompanying CVI may decrease SI concentration and might have influenced our results. This means that some other indicators of iron metabolism should be evaluated in further studies and special attention should be paid on non-transferrin bound iron (NTBI), a low molecule iron complex capable of initiating ROS formation [46–52]. Elevated level of NTBI was found in pathological conditions, such as hemochromatosis, diabetes and cardiovascular diseases [47,49,50]. Some studies have demonstrated that NTBI correlates positively with high SI level [46–48]. It may be suggested that in CVI patients with increased SI concentration, the existence of this most labile and redox active form of iron ions [51,52] is also very probable. It should be considered that iron-mediated ROS production can also occur in condition of this metal ions proper level. There is some evidence indicating that protein-bound iron can participate in oxidative stress [53,54]. During pathogenesis of CVI, the diapedesis of erythrocytes provokes cell lysis and the release of hemoglobin, which represents a potentially dangerous form of pro-oxidant iron [55]. It is proposed that iron can be liberated from the protein core, becoming a catalyst of hydroxyl radical formation [56].

These facts suggest that the exact explanation of the origin of iron ions taking part in the ROS generation during CVI development is still incomplete and requires further studies.

Conclusions

High concentration of MDA and lower UA level observed in CVI patients suggest that oxidative stress plays an important role in the pathogenesis of vein disease. The effect of oxidative stress seems to be compensated by the endogenous
antioxidant system, which is manifested by the increase in plasma TAC in CVI patients. The increase in SI concentration observed in early stage of CVI may enhance ROS formation, although only indirect evidence has been provided by the present study. More information on the ability of iron ions to produce ROS during CVI pathogenesis could be gained through the evaluation of NTBI concentration in CVI patients, particularly in those with elevated SI level.

Acknowledgements

We wish to thank Professor Geoffrey Shaw for his help with the English editing of this text.

REFERENCES:

1. Elsharawy MA, Naim MM, Abdelmaguid EM, Al-Mulhim AA: Role of sphaenous vein wall in the pathogenesis of primary varicose veins. Interact Cardiovasc Thorac Surg, 2007; 6: 219–24
2. Saharay M, Brosnan MJ, Fennell J et al: Oxidative stress and vascular disorders. Curr Opin Lipidol, 2007; 18: 698–98
3. Takase S, Schmid-Schonbein G, Bergan J: Leukocyte activation in patients with venous insufficiency. J Vasc Surg, 1999; 30: 148–56
4. Smith PD: Neutrophil activation and mediators of inflammation in chronic venous insufficiency. J Vasc Res, 1999; 36: 24–36
5. Ackermann Z, Seidenbaum M, Loewenthal E, Rubinow A: Overload of iron in skin of patients with varicose veins. Possible contributing role of iron accumulation in the progression of disease. Arch Dermatol, 1988; 124: 1376–78
6. Zamboni P, Izzo M, Fogato L et al: Urine haemosiderin: a novel marker to assess the severity of chronic venous disease. J Vasc Surg, 2003; 37: 152–56
7. Maiborodin IV, Pavlik EG, Egorov VA et al: Hemosiderin and siderophages in inguinal lymph nodes in chronic venous insufficiency of the legs. Arkh Patol, 2006; 68: 23–25
8. Zamboni P, Scapoli G, Lanzara V et al: Serum iron and MMP-9 variances in limbs affected by chronic venous disease and venous leg ulcers. Dermatol Surg, 2005; 31: 644–49
9. Buege JA, Aust SD: Microsomal lipid peroxidation. Method Enzymol, 1978; 12: 302–10
10. Jentsch AM, Bachmann H, Hurst P, Biesalski HK: Improved analysis of malondialdehyde in human body fluids. Free Radical Bio Med, 1996; 20: 251–56
11. Bartosz G, Janaszewska A, Karski D, Bartosz M: Simple determination of peroxyl radical trapping capacity. Biochim Biophys Acta, 1998; 14: 519–28
12. Hull DS, Green K, Thomas L, Alderman N: Hydrogen peroxide-mediated corneal endothelial damage: Induction by oxygen free radicals. Invest Ophthalmol Vis Sci, 1984; 25: 1245–53
13. Bishop CT, Mirza Z, Crapo JD, Freeman BA: Free radical damage to cultured porcine aortic endothelial cells and lung fibroblasts: modulation by cultured conditions. In Vitro Cell Dev Biol, 1985; 21: 229–36
14. Michalska M, Ghuba A, Dimitri PM et al: The role of polyphenols in cardiovascular disease. Med Sci Monit, 2010; 16(5): RA110–19
15. Bandypadhyay U, Das D, Banerjee RK: Reactive oxygen species: oxidative damage and pathogenesis. Curr Sci, 1995; 77: 658–66
16. Kozka M, Kryszcik W, Pietrzynka A, Stepniowska M: Obesity and its influence on reactive oxygen species (ROS) in the blood of patients with varicose veins of the lower limbs. Przegl Lek, 2009; 66: 213–17
17. Głowski J, Głowski S: Generation of reactive oxygen metabolites by the varicose vein wall. Eur J Vasc Endovasc Surg, 2002; 25: 550–55
18. Karapepe O, Unal O, Uğurlucan M et al: The impact of valvular oxidative stress on the development of venous stasis valvular oxidative stress and venous ulcers. Angiology, 2010; 61: 283–88
19. Kryśczyk W, Kozka M, Kazek Z, Stepniowska M: Selected indicators of the antioxidative system in the blood of patients with lower limb varicose veins. Acta Angiol, 2009; 15: 10–19
20. Yeoh-Ellerton S, Stacey MC: Iron and $\delta$-isopropionate levels in acute and chronic wounds. J Invest Dermatol, 2003; 121: 918–25
21. Chuang CC, Shiels, Chi CH et al: Serum total antioxidant capacity reflects severity of illness in patients with severe sepsis. Crit Care, 2006; 10: R36
22. Reinisch N, Kiechl S, Mayr C et al: Association of high plasma antioxidant capacity with new lesion formation in carotid atherosclerosis: a prospective study. Eur J Clin Invest, 1998; 28: 787–92
23. Goldknecht B, Demir M, Goldknecht S et al: Oxidative stress and total antioxidant capacity in diabetic and nondiabetic acute ischemic stroke patients. Clin Appl Thromb-Hem, 2009; 15: 695–700
24. James TJ, Hughes MA, Cherry GW, Taylor RP: Evidence of oxidative stress in chronic varicous ulcer. Wound Repair Regen, 2005; 13: 172–76
25. De Valk B, Marx J: Iron, atherosclerosis, and ischemic heart disease. Arch Intern Med, 1999; 159: 1542–48
26. Morrison HI, Semenciw RM, Mao Y, Wigle DT: Serum iron and risk of fatal acute myocardial infarction. Epidemiology, 1994; 5: 135–37
27. Salonen JT, Nyssonen K, Korpeila H et al: High stored iron levels are associated with excess risk of myocardial infarction in Eastern Finnish men. Circulation, 1992; 86: 803–11
28. Tyneczka M: Iron and transferin levels in the blood serum of patients with acute cerebral vascular disease depending on the clinical group and duration of stroke. Med Sci Monit, 1996; 2: 474–77
29. Kiechl S, Wilke J, Egger G et al: Body iron stores and the risk of carotid atherosclerosis. Prospective result from the Brunec study. Circulation, 1997; 96: 3300–7
30. Howes PS, Zacharski LR, Sullivan J, Chow B: Role of stored iron in atherosclerosis. J Vasc Nurs, 2008; 19: 108–16
31. Zacharski LR, Chow B, Lavorn PW et al: The iron and atherosclerosis study: a pilot study of reduction of body iron stores in atherosclerotic peripheral vascular disease. Am Heart J, 2000; 139: 337–45
32. Zamboni P, Izzo M, Tognazzo S et al: The overlapping of local iron overload and HFE mutation in venous leg ulcer pathogenesis. Free Radical Bio Med, 2006; 40: 1869–73
33. Pelcina A, Pelcina V, Pelcina M et al: Redox-dependent execution. FASEB J, 2006; 20: 1589–98
34. Morrison HI, Semenciw RM, Mao Y, Wigle DT: Serum iron and risk of fatal acute myocardial infarction. Epidemiology, 1994; 5: 135–37
35. Salonen JT, Nyssonen K, Korpeila H et al: High stored iron levels are associated with excess risk of myocardial infarction in Eastern Finnish men. Circulation, 1992; 86: 803–11
36. Tyneczka M: Iron and transferin levels in the blood serum of patients with acute cerebral vascular disease depending on the clinical group and duration of stroke. Med Sci Monit, 1996; 2: 474–77
37. Kiechl S, Wilke J, Egger G et al: Body iron stores and the risk of carotid atherosclerosis. Prospective result from the Brunec study. Circulation, 1997; 96: 3300–7
38. Howes PS, Zacharski LR, Sullivan J, Chow B: Role of stored iron in atherosclerosis. J Vasc Nurs, 2008; 19: 108–16
39. Zacharski LR, Chow B, Lavorn PW et al: The iron and atherosclerosis study: a pilot study of reduction of body iron stores in atherosclerotic peripheral vascular disease. Am Heart J, 2000; 139: 337–45
40. Zamboni P, Izzo M, Tognazzo S et al: The overlapping of local iron overload and HFE mutation in venous leg ulcer pathogenesis. Free Radical Bio Med, 2006; 40: 1869–73
41. Piette R: The influence of age upon serum iron in normal subjects. J Clin Pathol, 1952; 5: 10–15
42. Seltzer C, Mayer J: Serum iron and iron-binding capacity in adolescents. Am J Clin Nutr, 1963; 13: 354–61
43. Pinhas-Hamiel O, Newfield RS, Koren I et al: Greater prevalence of iron deficiency in overweight and obese children and adolescents. Int J Obes, 2003; 27: 416–18
44. Lecube A, Guerrero A, Losada E et al: Iron deficiency in obese postmenopausal women. Obesity, 2006; 14: 1724–30
45. al-Rafiie FN, Wikics DG, Wunke B et al: Serum non-transferrin-bound iron in beta-thalassemia major patients treated deferoxamine and L-1. Br J Haematol, 1992; 82: 431–36
46. Lee DH, Ding Yong L, Jacobs DR et al: Common presence of non-transferrin-bound iron among patients with type 2 diabetes. Diabetes Care, 2006; 29: 1090–95
47. Le Lan C, Loeal O, Cohen T et al: Redox active plasma iron in $\delta$282Y/$\delta$282Y hemochromatosis. Blood, 2005; 105: 4327–31
49. de Valk B, Addicks MA, Gosriwatana I et al: Non-transferrin-bound iron in serum of hereditary haemochromatosis heterozygotes. Eur J Clin Invest, 2000; 30: 248–51

50. Van der A DL, Marx JJ, Grobbee DE et al: Non-transferrin-bound iron and risk of coronary heart disease in postmenopausal woman. Circulation, 2006; 113: 1942–49

51. Kruszewski M: The role of labile iron pool in cardiovascular diseases. Act Biochim Pol, 2004; 51: 471–80

52. Koren A, Fink D, Admoni O et al: Non-transferrin bound labile plasma iron and iron overload in Sickle Cell Disease: a comparative study between Sickle Cell Disease and β-thalassemic patients. Eur J Haematol, 2010; 84: 72–78

53. Konijn AM, Glickstein H, Vainsman B et al: The cellular labile iron pool and intracellular ferritin in K562 cells. Blood, 1999; 94: 2128–34

54. Goldman DW, Breyer RJ, Yeh D, Brockner-Ryan B: Acellular hemoglobin-mediated oxidative stress toward endothelium: a role for ferryl iron. Am J Physiol, 1996; 275: H1046–53

55. Cagiatti A, Rossi C, Franceschini M, Innocenti D: The nature of skin pigmentation in chronic venous insufficiency: a preliminary report. Eur J Vasc Endovasc Surg, 2008; 35: 111–18

56. Alayash AI, Patel RP, Cashon RE: Redox reactions of hemoglobin and myoglobin: biological and toxicological implications. Antioxid Redox Signal, 2001; 3: 315–27